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Benzathine penicillin G is an important antibiotic for the treatment and prevention of group A streptococcal
infections associated with rheumatic fever and rheumatic heart disease. However, as rheumatic heart disease
has receded as a public health priority in most high-income settings, attention to the supply, manufacture, and
accessibility of benzathine penicillin G has declined. Concerns about the quality, efﬁcacy, and innovation of
the drug have emerged following plasma analysis and anecdotal reports from low-resource settings. This
review collates core issues in supply and delivery of benzathine penicillin G as a foundation for concerted
efforts to improve global quality and access. Opportunities for intervention and improvement are explored.From the *Telethon Insti-
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CC BY-NC-ND license.Rheumatic fever (RF) and rheumatic heart disease
(RHD) are an autoimmune sequel of group A streptococcal
(GAS) infections. Recurrences of RF accelerate progression
of cardiac valve damage, culminating in heart failure, ar-
rhythmias, and often fatalities. The global burden of RF/
RHD is signiﬁcanteconservatively estimated at 471,000
cases of RF annually and 233,000 deaths per year. At least
15.6 million people suffer from RF/RHD worldwide. RF/
RHD is a neglected disease of poverty endemic in low-
resource settings and some subpopulations in high-
income countries [1].
Antibiotics are essential for prophylaxis to prevent
recurrences of RF (secondary prophylaxis) and for treatment
of symptomatic GAS infections (primary prevention). Since
the 1950s, prophylaxis has been achieved via intramuscular
(IM) administration of benzathine penicillin G (BPG) [2].
Although other antibiotics have been used, BPG is a partic-
ularly effective agent for primary and secondary prevention
because its long half-life provides prolonged bactericidal
protection from GAS infection. With effective secondary
prophylaxis recurrence, the progression of RF to RHD can be
prevented [3,4]. A small number of oral alternatives for RF
secondary prophylaxis have been used; these are all less
effective than IM BPG in preventing recurrences of RF
[3,5,6]. Alternative regimes for individuals with severe
penicillin allergy or intolerance are addressed in most
RF/RHD treatment guidelines but are outside the scope of
this review [5,7e11].
This review presents an overview of the current issues
surrounding BPG for the management of RHD and RF.
A systematic search of peer-reviewed literature identiﬁed a
small number of basic science articles and commentaries
on BPG. Expanding bibliographic review identiﬁed a range
of other articles documenting concerns about supply,
quality, and access. These issues were explored withGLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 227-234targeted searches of public records revealing patent infor-
mation, commercial details, and correspondence.
PHARMACOLOGY OF BPG
Benzathine penicillin G is a crystalline powder formed
through the fusion of 2 penicillin G molecules and charac-
terized by very low solubility and in vivo hydrolysis
[2,12e14]. These features are associated with slow absorp-
tion from IM injection, producing prolonged therapeutic
serum concentrations [12,15]. Prolonged concentration in
serum provides excellent protection from GAS infection. No
GAS resistance to BPG has been documented in vitro [16].
The mechanism for the apparent persistent susceptibility of
GAS to BPG is relatively poorly understood [15,17,18].
DISEASES, DOSES, AND DEMANDS FOR BPG
From the 1950s, BPGwaswidely used as the ﬁrst list drug for
an array of conditions: syphilis, yaws, Lyme disease, and
pneumococcal prophylaxis in sickle cell disease [19e21].
However, development of new antibiotics has narrowed the
clinical indications for BPG. Conditions requiring BPG
treatment have also become less common in high-resource
settings, further shrinking demand. This section proﬁles
the existing indications for BPG, providing a foundation for
much-needed research work on the potential size of com-
mercial markets.
Secondary prophylaxis for RHD
The World Health Organization (WHO) deﬁnes secondary
prophylaxis as “the continuous administration of speciﬁc
antibiotics to patients with a previous attack of rheumatic
fever, or well-documented rheumatic heart disease. The
purpose is to prevent colonization or infection of the upper
respiratory tract with group A beta-hemolytic streptococci227
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228and the development of recurrent attacks of rheumatic
fever” [9]. The internationally accepted dose for secondary
prophylaxis with BPG in adults is 900 mg (1.2 million IU)
intramuscularly. There is some uncertainly over the opti-
mum frequency of administration; some papers suggest
2-weekly administration [22], others report very good
outcomes on a 3-weekly regime [23,24]. Most guidelines
recommend 4-weekly administration as a pragmatic
choice, with an option to escalate to 3-weekly adminis-
tration if there are unexplained recurrences or very high
risk [3,5,9,10,25]. The recommended BPG dose for chil-
dren varies between guidelines: 450 mg (0.6 million IU) up
to 20 kg in Australia; 450 mg up to 27 kg in American
Heart Association guidelines; and 450 mg up to 30 kg in
WHO guidelines [5,9,10].
The optimal duration of secondary prophylaxis is
controversial. In most guidelines, duration depends on the
initial presentation of RF and location within a high-risk
population [5,10]. An array of anecdotal factors have
been distilled into consensus guidelines for local imple-
mentation [7,10]. Exploring the indications for prolonged
prophylaxis is outside the scope of this review. However, it
is noteworthy that the minimum duration of secondary
prophylaxis in most guidelines is 10 years [5,7,9e11]. In
severe cases, lifelong regular BPG administration may be
recommended [5,10]. Missing even a single dose of BPG
raises the risk of recurrent RF and can undermine entire
secondary prophylaxis programs. Stability of supply is a
critical issue for programmatic success.Primary treatment of group A streptococcal
pharyngitis
Antibiotic treatment of symptomatic GAS pharyngitis is
widely recommended [5,7,9,10]. However, access to culture
or rapid antigen tests is limited in low-resource settings, and
may delay treatment. Evidence for empiric treatment of
childhood sore throats according to a clinical decision rule in
high-risk populations has recently been published [26]. A
single dose of BPG (between 225 g and 900 g depending on
weight) is recommended in high-risk settings or where oral
compliance is challenging [7,10]. Treatment of asymptom-
atic GAS carriers is not routine but may be considered in rare
circumstances, such as disease outbreaks in closed com-
munities [5,27,28].Syphilis
An estimated 12 million people are infected with the
spirochete Treponema pallidum [29]. T. pallidum is partic-
ularly responsive to penicillin in the form of BPG [30]. The
recommended dose is double the RF/RHD prophylaxis
dose at 1.44 g (2.4 million IU) as a single immediate dose
for primary syphilis or 3 doses for late syphilis [31]. There
is some evidence that use of oral azithromycin is compa-
rable to a single dose of BPG for treatment of early syphilis
[32]. However, BPG remains the only agent suitable fortreating pregnant women to prevent transmission to the
fetus and avert congenital syphilis in neonates [30,31].
Yaws
Yaws is a skin infection caused by the spirochete bacterium
Treponema pallidum subspecies pertenue, which is related to
the causative organism of syphilis. The disease is estimated
to affect approximately half a million people, predomi-
nantly children in low-resource rural areas [33]. The
burden of yaws in Africa, South East Asia, and the Paciﬁc
Islands parallels the particular persistence of RF/RHD in
resource-limited settings. Treatment of yaws has tradi-
tionally been with 1.2 MU of IM BPG for adults and 0.6
MU IM BPG for children [34]. Evidence for the role of oral
azithromycin as a treatment of choice for yaws is emerging,
potentially reducing demand in the BPG market [35]
PAST AND PRESENT BPG SUPPLIES
BPG was developed by J. Lester Szabo in 1951, and the ﬁrst
BPG patent appears to have been held in the United States
in 1953 by Bruce [2,36,37]. Advances in stabilizing this
original powdered formulation were patented in subsequent
years [37]. Initial clinical application was for the treatment of
syphilitic infections, spurring considerable demand, com-
mercial interest, and a variety of brandedproducts throughout
the 1950s [36,38]. The patents, production, and formulation
of powdered BPG over the last 60 years is difﬁcult to track
amid a crowded manufacturing market, frequent stock out-
ages, and changes in suppliers [39e43].
A pre-mixed liquid formulation of BPG has been
developed, eliminating the need for a dilutant, but requiring
refrigeration. The initial patent on this new product was ﬁrst
held by Wyeth under the brand name Bicillin L-A, a 2-ml
formulation distributed in a Bicillin Tubex injector [15].
Wyeth’s Bicillin L-A, distributed by Aspen Pharmaceuticals,
was introduced into the Australia market in 1995 and
became the sole source of BPG to the country [44]. Industry
statements suggest that global rights to Bicillin L-A were
transferred to U.S.-based King Pharmaceuticals (reportedly
owned by Monarch at this time) in August 2005 [39,45,46].
Some conﬂicting reports suggest that the patent rights had
been transferred years earlier, but that Wyeth had continued
to produce for King under contract [47]. In 2007, the U.S.
Food and Drug Administration approved King Pharmaceu-
tical to produce Bicillin L-A at a new manufacturing and
production facility in Michigan, USA [48]. A company press
release from that time records King Pharmaceuticals as the
only manufacturer of Bicillin L-A in the United States [48].
Pﬁzer acquired King/Monarch Pharmaceuticals in 2010 and
Wyeth in 2009 and now appears to be the sole provider
of the suspension formulation of BPG in high-resource set-
tings [49].
In this complicated patent and manufacturing land-
scape, shortages of BPG have occurred. Details of stock
outages have been best documented in high-resource set-
tings with pockets of endemic RF/RHD in vulnerableGLOBAL HEART, VOL. 8, NO. 3, 2013
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populations. Supply of BPG for secondary prophylaxis was
limited in countries of the former Yugoslavia in the early
1990s [50]. Shortages have occurred in North America
from 2002 when Wyeth-Ayerst stopped producing BPG
from a Canadian plant [51,52]. Liquid Bicillin-LA stock
outages occurred in Australia and New Zealand between
2001 and 2008 [15,53]. In the United States, shortages
were notiﬁed to the Center for Disease Control in 2005; by
2010, 15% of 353 surveyed directors of pharmacy were
still dealing with shortages in America [54,55]. A World
Heart Federation survey of healthcare providers who treat
patients with RF/RHD prophylaxis collected data from 24
countries in Africa, the Asia-Paciﬁc region, and Central and
South America in 2011 [56]. Minimal access to BPG was
reported in almost all settings, with some respondents
indicating no access to BPG at all [56]. Of 39 respondents,
35% indicated that their BPG supply is inadequate to treat
all of their patients using recommended prophylaxis
schedules [56].
COST OF BPG
Reliable data on the purchase price of BPG is difﬁcult to
secure. Powdered BPG is available to some providers through
the support of the United Nations Children’s Fund pooled
procurement [57]. A 2010 report from the United Nations
Children’s Fund records 2.4 million IU vials of powdered
benzathine benzylpenicillin at a median of US$0.31 per dose.
A 2010 human immunodeﬁciency virus guide for Zambia
documents Monarch-branded 1.2 million IU of pre-mixed
BPG priced at $57.60 [58]. South African researchers used a
value of US $1 in 2010 (sensitivity range 0 to 13), for a single
vial of powdered BPG in a recent cost-effectiveness analysis
guided by local pharmacy data [26]. A recent newspaper
report from Kenya suggests the cost of a single dose of
BPG costs Sh250, approximately US$2.90 [59]. In Australia,
a 900-mg dose of Pﬁzer-branded Bicillin L-A is listed in the
Pharmaceutical Beneﬁts Scheme at a cost of AU$29.32
(US$29.85) per dose [60]. This is comparable with the same
product in the New Zealand Pharmaceutical Schedule, which
indicates a price of NZ $31.50 (US$25.03) (http://www.
pharmac.health.nz/ckeditor_assets/attachments/15/sched.pdf).
Finally, understanding the uses and supply of BPG has
been confused by a number of similarly named products.
In particular, Bicillin C-R (controlled release) and Bicillin
A-P (all purpose) [15,61,62]. These formulations contain
procaine penicillin G and/or aqueous penicillin, which
achieve higher and shorter serum concentration levels after
IM administration. Combinations of BPG and procaine
penicillin G have been proposed for the treatment of res-
piratory tract infections, scarlet fever, and skin infections,
but they are not suitable for RF secondary prophylaxis
[63].
BPG QUALITY
The paucity of readily accessible quality control guidelines
in BPG manufacturing has been a source of concern withinGLOBAL HEART, VOL. 8, NO. 3, 2013
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to obtain process information from manufacturers have
been unsuccessful despite a number of concerted efforts
[46,66]. In Canada, 2 “notice of compliance” documents
have been issued for branded, liquid formulation Bicillin L-
A (Pﬁzer and King); those documents represent compliance
with local Food and Drug Regulations [67]. The need for
continuous quality improvement activities to address
different preparations of BPG has also been identiﬁed by
WHO with little effect [68].
Efﬁcacy
In the absence of readily available manufacturing standards
or chemical composition assays, the efﬁcacy of BPG for-
mulations must be determined from clinical testing. Anal-
ysis of BPG is complicated by its prolonged half-life,
necessitating lengthy and potentially expensive follow-up
[69]. This is important for U.S. Food and Drug Adminis-
tration licensing of generic medications, which evaluates
bioequivalence via a plasma concentration-time curve from
zero to complete drug excretion [69,70].
Secondary prophylaxis for RF/RHD is thought to
require a minimum serum concentration of 0.02 mg/ml
BGP to prevent GAS infection, based on a reported mini-
mum inhibitory concentration 90 of 0.0016 [66,71]. The
oft-recommended 28-day dosing interval of BPG is calcu-
lated to keep serum concentrations above this therapeutic
threshold in order to prevent GAS infection. However,
there are well-founded concerns about the variability of
penicillin serum concentration from an array of manufac-
turers over a period of some years [46,65,66]. In a recent
trial, young American military recruits received a single stat
dose of 1.2 MU of BPG; mean serum concentrations were
less than the minimum serum concentration of 0.02 mg/ml
by day 9 after administration in one-half of the subjects.
Generalizing these results to the RHD secondary prophy-
laxis population suggests that patients may be unprotected
from GAS infection for up to 19 days prior to the next dose
administration [66]. A meta-analysis of 37 similar studies
evaluated trends in therapeutic penicillin serum concen-
trations; investigators have reported that the duration of
therapeutic serum concentrations is signiﬁcantly shorter in
studies since 1990 than it is in data from earlier decades
[71]. This raises signiﬁcant concerns about the effective-
ness of contemporary secondary prophylaxis programs.
Safety
Generally accepted international data suggests that the
incidence of allergic reactions to monthly BPG injection is
3.2% and anaphylactic reactions is 0.2% [9,72]. However,
anecdotal reports of adverse reactions appear to have
increased in recent years, in conjunction with concerns
about medication quality. Three deaths documented in
Zimbabwe in 2000 were associated with BPG from 3
different manufacturers [73]. A high frequency of
anaphylaxis events has also been reported in World Heart229
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least 1 anaphylactic reaction, and 21% of all providers
reported that they have had a patient die due to anaphy-
laxis after BPG injection [56]. At present, it is impossible to
determine whether adverse drug reactions are caused by
penicillin, reactions to other components of the medica-
tion/dilatant, unrelated to BPG administration, or mis-
classiﬁed reactions. The role of vasovagal reactions to IM
injection, particularly in diverse cultural settings, may also
be an important area for further research. A system for
reporting adverse drug events is important for BPG as a
way of monitoring both penicillin safety and perhaps a
proxy guide to BPG quality [74].
Administration challenges
Powdered BPG forms a suspension when reconstituted prior
to administration. This incomplete dissolution predisposes
to precipitation and needle blockage during administration
[75].Worldwide anecdotal reports suggest this precipitation
is a common problem. For example, when Australia used
powdered Pan Benz during the 2006 stock outage of Bicillin
L-A, up to 40% of injections of Pan Benz were affected by
needle blockages. Concerns were reportedly raised to the
Therapeutic Goods Administration via the Centers for Dis-
ease Control, though no record of subsequent regulatory
intervention can be found [76]. Many countries are depen-
dent on powdered BPG for the near future, and effective
administration remains an unmet challenge.
BPG AS AN ESSENTIAL MEDICINE
WHO has biennially produced a list of essential drugs since
1977, forming the foundation for 156 national Essential
Medicines Lists (EML) [77,78]. The success of EML spur-
red the development of further speciﬁc lists, including the
Interagency List of Essential Medicines for Reproductive
Health in 2006 and the Essential Medicines List for Chil-
dren (EMLc) in 2007 [79,80]. These lists were supple-
mented by a WHO publication on model prescribing
information for RF/RHD in 1999 [68].
The adult 1.2 million MU dose of BPG appears in the
(current) 17th edition 2011 EML of WHO [81]. The pe-
diatric EML also includes BPG but only at the standard
adult dose. Theoretically, this could be problematic for
countries with a high burden of RF/RHD in young children
or with widespread growth stunting. The inclusion of pe-
diatric doses for RHD prophylaxis received speciﬁc atten-
tion during the drafting of the EMLc, including in a
detailed report [80,82]. Similarly, BPG appears on the
Interagency List of Essential Medicines for Reproductive
Health in a 1.44 g (2.4 million IU) form for treatment of
syphilis [79]. It is unclear whether the recommended for-
mulations of BPG, which appear on the WHO EML, are
translated to national level EMLs. This requires a targeted
investigation to evaluate which countries with a high
burden of RHD have adopted the EML recommendations
to national formularies.DELIVERY MECHANISMS
Delivering each injection in secondary prophylaxis regimes
is a global challenge. In many settings, far fewer than 80%
of scheduled injections are delivered, signiﬁcantly
increasing the risk of rheumatic fever [83e87]. Although
the link between the pain of BPG administration and
compliance has little published support, it is reasonable to
assume that discomfort is a factor for young people
[10,88,89]. Adherence with secondary prophylaxis is crit-
ically low in many settings; any attempt to improve
acceptability of BPG warrants vigorous investigation.
Some centers employ techniques to reduce the pain of
IM injections, such as use of smaller gauge needles, direct
pressure, slow injections, and distractions [10]. In some
programs, local anesthetic is routinely used as a dilutant for
powdered BPG to reduce injection pain [90]. There is good
evidence that the practice is effective at relieving pain,
without reducing absorption or serum concentration of
BPG [10,91,92]. However, pain could be further mini-
mized by alternative delivery mechanisms, potentially an
implantable device.
An implantable or longer acting BPG delivery device
would be a more appropriate and acceptable mechanism
for delivering secondary prophylaxis [64,93,94]. Although
this is a conceptually promising approach, there has been
little reported innovation in this ﬁeld.
IMPROVING BPG ACCESS
Control of RF and RHD depends on supply, procurement,
and delivery of BPG. Vaccine prospects remain years from
clinical implementation, forcing primary and secondary pre-
vention activities to the fore [95]. Improved global burden of
disease data and echocardiographic screening programs are
likely to expand demand for BPG, particular if echocardiog-
raphy moves from a descriptive to an interventional phase
[95,96]. Thus, improving access to BPG and supporting
compliance should be a key priority for the RHD community
[64,95]. Three domains of intervention are required.
Technical and clinical research interventions
Technical manufacturing standards or speciﬁcations for
BPG have not been located during this review, nor in
earlier attempts by other investigators [64]. Some speciﬁ-
cations may reside with patent holders for pre-mixed BPG.
Older standards for powdered formulations may be held by
regulatory agencies that are inaccessible to electronic re-
view. Locating and distributing of nonproprietary stan-
dards is needed in order to evaluate generic formulations
and ensure standardization. Simple assays for establishing
the quality and purity of BPG may also need to be devel-
oped to assist procurement agencies in purchasing
decisions.
Updated data for anaphylaxis and adverse drug reactions
is essential, particular if use of BPG is to be expanded. Adverse
drug reaction data may be accessible by interrogating existing
national level databases or supporting the development ofGLOBAL HEART, VOL. 8, NO. 3, 2013
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pharmaco-vigilance programs [97]. In settings without any
mechanism for reporting drug events, a BGP-speciﬁc register
may be needed as an interim measure.
Market interventions and research partnerships
interventions
Increasing attention to the market dynamics of pharma-
ceutical products in low- and middle-income countries has
emerged in recent years. Organizations such as the United
Nations Children’s Fund, UNITAID, Drugs for Neglected
Diseases Initiative, and the Medicines Patent Pool illustrate
new ways of tackling access to medicines barriers
[98e101]. The RHD community should seek engagement
with these kinds of organizations to tackle BPG supply and
provide ongoing, disease-speciﬁc, technical support. Part-
nerships with other diseases still using BPG—yaws and
congenital syphilis—are also likely to be important op-
portunities for strengthening an economically viable BPG
market. Developing relationships with the pharmaceutical
industry to foster research, development, manufacturing
standards, and quality outcomes is a likely prerequisite for
success.
Systems, policy, and applied research
interventions
BPG is already incorporated in the core and subsidiary
WHO EML. Further research is needed to compare na-
tional formularies against the EML; if BPG has been
omitted, advocacy for inclusion and supply will be needed
at a national level. At a local level, documenting costs,
stock outages, and administration challenges will be a
critical metric of success for global level advocacy and
partnerships. Innovative inclusion of people living with RF/
RHD may be possible. For example, Stop Stock-outs! is a
campaign for consumers to report medication shortages by
text message in Kenya and Uganda [102]. Constructive,
sustainable improvements at a local level require a health
systems approach. A systems framework allows consumers,
prescribers, and procurers to address forecasting, pur-
chasing, delivery, cost, and other macrodeterminants of
actual medication uptake [103].
SUMMARY
Securing and delivering high-quality supplies of BPG is a
surmountable challenge; powdered formulations are off-
patent, ﬁxed-dose, do not require a cold chain, and de-
mand can be forecast in predictable volumes for many years.
In comparison to the complexities of early antiretroviral
regimes and vaccination efforts, universal access to BPG is
eminently achievable. Working with novel partners provides
an opportunity to foster integration, avoiding the develop-
ment of “unsustainable monolithic programs” for RHD
control [9]. This review and commentary provides a
compilation on the historic and existing issues for BPG
supply and delivery. Global institutional leadership will beGLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 227-234required to move forward on priority issues for improving
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